Taken together, our results establishJS25 as a therapeutically relevant BTKi, with demonstrated antiproliferativeeffects and improved selectivity profile, and we envisage its clinicaluse against hematological cancers and autoimmune diseases. The gene discussed is IBTK; the disease is autoimmune disease.